EA200000274A3 - Способы получения и промежуточные соединения для получения противораковых соединений - Google Patents

Способы получения и промежуточные соединения для получения противораковых соединений

Info

Publication number: EA200000274A3
Authority: EA; Eurasian Patent Office
Prior art keywords: obtaining; tray; compounds; methods; intermediate connections
Prior art date: 1999-03-31

Application number

EA200000274A

Other languages

English (en)

Other versions

EA200000274A2 (ru

EA004654B1 (ru

Inventor

Ричард Шелтон Лехнер

Тимоти Норрис

Динос Пол Сантафьянос

Original Assignee

Пфайзер Продактс Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-31

Filing date

2000-03-30

Publication date

2003-02-27

2000-03-30 Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.

2000-10-30 Publication of EA200000274A2 publication Critical patent/EA200000274A2/ru

2003-02-27 Publication of EA200000274A3 publication Critical patent/EA200000274A3/ru

2004-06-24 Publication of EA004654B1 publication Critical patent/EA004654B1/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0002—Preliminary treatment
- C22B15/0004—Preliminary treatment without modification of the copper constituent
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0063—Hydrometallurgy
- C22B15/0065—Leaching or slurrying
- C22B15/0067—Leaching or slurrying with acids or salts thereof
- C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Mechanical Engineering (AREA)
Manufacturing & Machinery (AREA)
Metallurgy (AREA)
Materials Engineering (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

EA200000274A 1999-03-31 2000-03-30 Способы получения и промежуточные соединения для получения противораковых соединений EA004654B1 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12707299P	1999-03-31	1999-03-31

Publications (3)

Publication Number	Publication Date
EA200000274A2 EA200000274A2 (ru)	2000-10-30
EA200000274A3 true EA200000274A3 (ru)	2003-02-27
EA004654B1 EA004654B1 (ru)	2004-06-24

Family

ID=22428179

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EA200201245A EA005892B1 (ru)	1999-03-31	2000-03-30	Способ получения противораковых соединений
EA200000274A EA004654B1 (ru)	1999-03-31	2000-03-30	Способы получения и промежуточные соединения для получения противораковых соединений
EA200201244A EA005561B1 (ru)	1999-03-31	2000-03-30	Способ получения промежуточных соединений, применимых для получения противораковых соединений

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EA200201245A EA005892B1 (ru)	1999-03-31	2000-03-30	Способ получения противораковых соединений

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EA200201244A EA005561B1 (ru)	1999-03-31	2000-03-30	Способ получения промежуточных соединений, применимых для получения противораковых соединений

Country Status (49)

Country	Link
US (1)	US6476040B1 (ru)
EP (1)	EP1044969B1 (ru)
JP (2)	JP3420549B2 (ru)
KR (2)	KR100430210B1 (ru)
CN (2)	CN1215061C (ru)
AP (2)	AP1655A (ru)
AR (1)	AR018705A1 (ru)
AT (1)	ATE348098T1 (ru)
AU (2)	AU781402B2 (ru)
BG (1)	BG65194B1 (ru)
BR (1)	BRPI0001486B8 (ru)
CA (2)	CA2427221C (ru)
CO (1)	CO5160273A1 (ru)
CR (1)	CR6165A (ru)
CZ (1)	CZ299426B6 (ru)
DE (1)	DE60032275T2 (ru)
DK (1)	DK1044969T3 (ru)
DZ (1)	DZ3030A1 (ru)
EA (3)	EA005892B1 (ru)
EE (1)	EE04589B1 (ru)
EG (1)	EG22506A (ru)
ES (1)	ES2278578T3 (ru)
GE (1)	GEP20022653B (ru)
GT (1)	GT200000037A (ru)
HR (1)	HRP20000182B1 (ru)
HU (1)	HU227698B1 (ru)
ID (1)	ID25427A (ru)
IL (2)	IL135245A0 (ru)
IS (1)	IS2468B (ru)
MA (1)	MA25087A1 (ru)
MY (1)	MY136270A (ru)
NO (2)	NO321952B1 (ru)
NZ (2)	NZ503683A (ru)
OA (1)	OA11335A (ru)
PA (1)	PA8491901A1 (ru)
PE (1)	PE20001599A1 (ru)
PL (1)	PL339330A1 (ru)
PT (1)	PT1044969E (ru)
RS (1)	RS49836B (ru)
SG (2)	SG121687A1 (ru)
SK (1)	SK287339B6 (ru)
SV (1)	SV2002000047A (ru)
TN (1)	TNSN00064A1 (ru)
TR (1)	TR200000837A2 (ru)
TW (1)	TW553939B (ru)
UA (2)	UA80955C2 (ru)
UY (1)	UY26086A1 (ru)
YU (1)	YU13200A (ru)
ZA (1)	ZA200001586B (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6706721B1 (en)	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (ru)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
US7087613B2 (en)	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP1506962B1 (en)	2000-10-20	2008-07-02	Eisai R&D Management Co., Ltd.	Nitrogen-containing aromatic heterocycles
WO2003000188A2 (en)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
US7078409B2 (en)	2002-03-28	2006-07-18	Beta Pharma, Inc.	Fused quinazoline derivatives useful as tyrosine kinase inhibitors
AU2003249212C1 (en)	2002-07-15	2011-10-27	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
US7148231B2 (en)	2003-02-17	2006-12-12	Hoffmann-La Roche Inc.	[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7994159B2 (en)	2003-03-10	2011-08-09	Eisai R&D Management Co., Ltd.	c-Kit kinase inhibitor
US8309562B2 (en) *	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
NZ544472A (en)	2003-07-03	2009-04-30	Myriad Genetics Inc	Compounds and therapeutical use thereof
BRPI0414489A8 (pt)	2003-09-16	2019-01-15	Astrazeneca Ab	derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
ES2925655T3 (es)	2003-09-26	2022-10-19	Exelixis Inc	Moduladores c-Met y métodos de uso
CN101337930B (zh)	2003-11-11	2010-09-08	卫材R&D管理有限公司	脲衍生物的制备方法
DK1746999T3 (da) *	2004-05-06	2012-01-23	Warner Lambert Co	4-phenylamino-quinazolin-6-yl-amider
EP1797881B1 (en)	2004-09-17	2009-04-15	Eisai R&D Management Co., Ltd.	Medicinal composition with improved stability and reduced gelation properties
CA2592900A1 (en)	2005-01-03	2006-07-13	Myriad Genetics Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
US7625911B2 (en) *	2005-01-12	2009-12-01	Mai De Ltd.	Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
DK1859793T3 (da) *	2005-02-28	2011-08-01	Eisai R&D Man Co Ltd	Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
WO2007015569A1 (ja) *	2005-08-01	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) *	2005-11-07	2009-02-26	Eisai R & D Management Co., Ltd.	USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumor agent against multiple myeloma
US20090209580A1 (en) *	2006-05-18	2009-08-20	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
EP2044939A1 (en) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutic agent for liver fibrosis
EP2054393A1 (en)	2006-07-28	2009-05-06	Synthon B.V.	Crystalline erlotinib
KR101472600B1 (ko)	2006-08-28	2014-12-15	에자이 알앤드디 매니지먼트 가부시키가이샤	미분화형 위암에 대한 항종양제
US8372856B2 (en) *	2006-10-27	2013-02-12	Synthon Bv	Hydrates of erlotinib hydrochloride
AU2008205847A1 (en)	2007-01-19	2008-07-24	Eisai R & D Management Co., Ltd.	Composition for treatment of pancreatic cancer
KR101445892B1 (ko)	2007-01-29	2014-09-29	에자이 알앤드디 매니지먼트 가부시키가이샤	미분화형 위암 치료용 조성물
KR20100014512A (ko) *	2007-02-21	2010-02-10	낫코 파마 리미티드	엘로티닙 하이드로클로라이드의 신규한 다형체 및 제조방법
KR20140069232A (ko)	2007-04-04	2014-06-09	시플라 리미티드	에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) *	2007-06-25	2009-01-08	Ales Gavenda	Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
ES2492645T3 (es)	2007-07-11	2014-09-10	Hetero Drugs Limited	Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
US20090124642A1 (en) *	2007-08-23	2009-05-14	Augusto Canavesi	Crystalline forms of Erlotinib HCI and formulations thereof
MX2010002081A (es) *	2007-08-23	2010-06-01	Plus Chemicals Sa	Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
US20090076042A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched erlotinib
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009210098B2 (en) *	2008-01-29	2013-06-13	Eisai R & D Management Co., Ltd.	Combined use of angiogenesis inhibitor and taxane
US20090269354A1 (en) *	2008-03-28	2009-10-29	Concert Pharmaceuticals, Inc.	Quinazoline derivatives and methods of treatment
WO2010005924A1 (en) *	2008-07-07	2010-01-14	Plus Chemicals Sa	Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko)	2008-10-01	2012-04-06	주식회사종근당	Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) *	2008-10-08	2010-04-15	Apotex Pharmachem Inc.	Processes for the preparation of erlotinib hydrochloride
KR101733773B1 (ko)	2009-01-16	2017-05-10	엑셀리시스, 인코포레이티드	Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP2411373B1 (en)	2009-03-26	2015-10-21	Ranbaxy Laboratories Limited	Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en)	2009-11-12	2012-09-19	Ranbaxy Laboratories Limited	Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en)	2009-12-02	2011-06-09	Ultimorphix Technologies B.V.	Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
RU2560683C2 (ru)	2010-06-25	2015-08-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
WO2012028861A1 (en)	2010-07-23	2012-03-08	Generics [Uk] Limited	Pure erlotinib
IT1402029B1 (it)	2010-10-14	2013-08-28	Italiana Sint Spa	Procedimento per la preparazione di erlotinib
KR101762999B1 (ko)	2011-04-18	2017-07-28	에자이 알앤드디 매니지먼트 가부시키가이샤	종양 치료제
EP2714937B1 (en)	2011-06-03	2018-11-14	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) *	2011-06-21	2013-12-11	天津市汉康医药生物技术有限公司	喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) *	2012-05-25	2016-08-31	浙江九洲药业股份有限公司	一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en)	2012-09-04	2017-03-14	Shilpa Medicare Limited	Crystalline erlotinib hydrochloride process
US9334239B2 (en)	2012-12-21	2016-05-10	Eisai R&D Management Co., Ltd.	Amorphous form of quinoline derivative, and method for producing same
WO2014118737A1 (en)	2013-01-31	2014-08-07	Ranbaxy Laboratories Limited	Erlotinib salts
US10517861B2 (en)	2013-05-14	2019-12-31	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) *	2013-05-28	2015-03-25	埃斯特维华义制药有限公司	一种制备盐酸厄洛替尼晶型f的方法
KR102329681B1 (ko)	2014-08-28	2021-11-23	에자이 알앤드디 매니지먼트 가부시키가이샤	고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2908441A1 (en)	2014-10-28	2016-04-28	Cerbios-Pharma Sa	Process for the preparation of erlotinib
WO2016136745A1 (ja)	2015-02-25	2016-09-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体の苦味抑制方法
WO2016140717A1 (en)	2015-03-04	2016-09-09	Merck Sharp & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es)	2015-06-16	2021-12-16	Prism Biolab Co Ltd	Antineoplásico
EP3338779B1 (en)	2015-08-20	2021-06-30	Eisai R&D Management Co., Ltd.	Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
CN105884653A (zh) *	2016-06-08	2016-08-24	浙江汇能生物股份有限公司	一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) *	2016-08-26	2017-01-04	宁波圣达精工智能科技有限公司	一种阻燃智能密集书架的制备方法
RU2750539C2 (ru)	2017-02-08	2021-06-29	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Фармацевтическая композиция для лечения опухоли
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4747498A (en) *	1986-06-27	1988-05-31	Sunbeam Plastics Corporation	Safety dispensing closure-container package
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
JP2657760B2 (ja) *	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
ES2161290T3 (es) *	1995-03-30	2001-12-01	Pfizer	Derivados de quinazolina.
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
EP0880508B1 (en)	1996-02-13	2003-04-16	AstraZeneca AB	Quinazoline derivatives as vegf inhibitors
DK0885198T3 (da)	1996-03-05	2002-03-25	Astrazeneca Ab	4-Anilinoquinazolinderivater
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6225499B1 (en)	1997-07-14	2001-05-01	Catalytica Pharmaceuticals, Inc.	Process for preparing aminoarylacetylenes
ATE295839T1 (de)	1998-04-29	2005-06-15	Osi Pharm Inc	N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat

2000
- 2000-03-03 YU YU13200A patent/YU13200A/sh unknown
- 2000-03-03 RS YUP-132/00A patent/RS49836B/sr unknown
- 2000-03-10 OA OA1200000071A patent/OA11335A/en unknown
- 2000-03-14 CR CR6165A patent/CR6165A/es unknown
- 2000-03-17 PA PA20008491901A patent/PA8491901A1/es unknown
- 2000-03-20 AT AT00302256T patent/ATE348098T1/de not_active IP Right Cessation
- 2000-03-20 ES ES00302256T patent/ES2278578T3/es not_active Expired - Lifetime
- 2000-03-20 DK DK00302256T patent/DK1044969T3/da active
- 2000-03-20 DE DE60032275T patent/DE60032275T2/de not_active Expired - Lifetime
- 2000-03-20 PT PT00302256T patent/PT1044969E/pt unknown
- 2000-03-20 EP EP00302256A patent/EP1044969B1/en not_active Expired - Lifetime
- 2000-03-21 IS IS5411A patent/IS2468B/is unknown
- 2000-03-22 CO CO00020444A patent/CO5160273A1/es unknown
- 2000-03-23 IL IL13524500A patent/IL135245A0/xx not_active IP Right Cessation
- 2000-03-23 IL IL168036A patent/IL168036A/en not_active IP Right Cessation
- 2000-03-27 TW TW089105605A patent/TW553939B/zh not_active IP Right Cessation
- 2000-03-27 UA UA20040503766A patent/UA80955C2/uk unknown
- 2000-03-27 UA UA2000031727A patent/UA70928C2/ru unknown
- 2000-03-27 BR BRPI0001486A patent/BRPI0001486B8/pt not_active IP Right Cessation
- 2000-03-27 SG SG200001746A patent/SG121687A1/en unknown
- 2000-03-27 SK SK444-2000A patent/SK287339B6/sk not_active IP Right Cessation
- 2000-03-27 EG EG20000364A patent/EG22506A/xx active
- 2000-03-27 ID IDP20000240A patent/ID25427A/id unknown
- 2000-03-27 SG SG200302185A patent/SG115536A1/en unknown
- 2000-03-28 AU AU22620/00A patent/AU781402B2/en not_active Expired
- 2000-03-28 BG BG104278A patent/BG65194B1/bg unknown
- 2000-03-29 AP APAP/P/2003/002757D patent/AP1655A/en active
- 2000-03-29 JP JP2000091300A patent/JP3420549B2/ja not_active Expired - Lifetime
- 2000-03-29 MA MA25940A patent/MA25087A1/fr unknown
- 2000-03-29 CA CA002427221A patent/CA2427221C/en not_active Expired - Lifetime
- 2000-03-29 CA CA002302965A patent/CA2302965C/en not_active Expired - Lifetime
- 2000-03-29 DZ DZ000059A patent/DZ3030A1/xx active
- 2000-03-29 AP APAP/P/2000/001778A patent/AP1265A/en active
- 2000-03-29 UY UY26086A patent/UY26086A1/es not_active Application Discontinuation
- 2000-03-29 AR ARP000101413A patent/AR018705A1/es active IP Right Grant
- 2000-03-29 ZA ZA200001586A patent/ZA200001586B/xx unknown
- 2000-03-29 TN TNTNSN00064A patent/TNSN00064A1/fr unknown
- 2000-03-29 MY MYPI20001252A patent/MY136270A/en unknown
- 2000-03-30 SV SV2000000047A patent/SV2002000047A/es not_active Application Discontinuation
- 2000-03-30 HU HU0001353A patent/HU227698B1/hu unknown
- 2000-03-30 EA EA200201245A patent/EA005892B1/ru not_active IP Right Cessation
- 2000-03-30 PL PL00339330A patent/PL339330A1/xx not_active Application Discontinuation
- 2000-03-30 NZ NZ503683A patent/NZ503683A/en not_active IP Right Cessation
- 2000-03-30 EE EEP200000255A patent/EE04589B1/xx not_active IP Right Cessation
- 2000-03-30 US US09/538,635 patent/US6476040B1/en not_active Expired - Lifetime
- 2000-03-30 EA EA200000274A patent/EA004654B1/ru not_active IP Right Cessation
- 2000-03-30 KR KR1020000016386A patent/KR100430210B1/ko not_active Expired - Lifetime
- 2000-03-30 NO NO20001648A patent/NO321952B1/no not_active IP Right Cessation
- 2000-03-30 NZ NZ512818A patent/NZ512818A/xx not_active IP Right Cessation
- 2000-03-30 GT GT200000037A patent/GT200000037A/es unknown
- 2000-03-30 TR TR2000/00837A patent/TR200000837A2/xx unknown
- 2000-03-30 EA EA200201244A patent/EA005561B1/ru not_active IP Right Cessation
- 2000-03-30 CZ CZ20001155A patent/CZ299426B6/cs not_active IP Right Cessation
- 2000-03-30 PE PE2000000277A patent/PE20001599A1/es not_active Application Discontinuation
- 2000-03-31 CN CNB001045954A patent/CN1215061C/zh not_active Expired - Lifetime
- 2000-03-31 HR HR20000182A patent/HRP20000182B1/xx not_active IP Right Cessation
- 2000-03-31 GE GEAP20005284A patent/GEP20022653B/en unknown
- 2000-03-31 CN CNB2005100763600A patent/CN100351242C/zh not_active Expired - Lifetime
2002
- 2002-07-29 KR KR10-2002-0044610A patent/KR100430209B1/ko not_active Expired - Lifetime
- 2002-12-12 JP JP2002360742A patent/JP4074509B2/ja not_active Expired - Lifetime
2005
- 2005-04-08 AU AU2005201494A patent/AU2005201494B2/en not_active Expired
- 2005-10-13 NO NO20054715A patent/NO324745B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EE04589B1 (et)	2006-02-15
US6476040B1 (en)	2002-11-05
EA200201245A1 (ru)	2003-04-24
HUP0001353A2 (hu)	2001-05-28
CA2427221C (en)	2008-09-16
EA200201244A1 (ru)	2003-04-24
NO321952B1 (no)	2006-07-24
KR100430209B1 (ko)	2004-05-03
GEP20022653B (en)	2002-03-25
EP1044969A3 (en)	2000-11-29
AP2000001778A0 (en)	2000-03-31
AU2262000A (en)	2000-10-05
BR0001486A (pt)	2001-05-02
AU2005201494A1 (en)	2005-05-05
CN100351242C (zh)	2007-11-28
JP2003176274A (ja)	2003-06-24
AU2005201494B2 (en)	2008-02-07
ZA200001586B (en)	2001-10-01
EA005561B1 (ru)	2005-04-28
MY136270A (en)	2008-09-30
BG65194B1 (bg)	2007-06-29
HU227698B1 (en)	2011-12-28
CZ20001155A3 (cs)	2001-03-14
BRPI0001486B1 (pt)	2019-01-29
CA2427221A1 (en)	2000-09-30
IL135245A0 (en)	2001-05-20
NO20054715L (no)	2000-10-02
BG104278A (en)	2001-08-31
EE200000255A (et)	2000-12-15
SG121687A1 (en)	2006-05-26
KR100430210B1 (ko)	2004-05-03
CR6165A (es)	2008-10-10
UA80955C2 (en)	2007-11-26
HRP20000182B1 (en)	2007-10-31
IL168036A (en)	2006-12-10
DZ3030A1 (fr)	2004-03-27
TR200000837A2 (tr)	2000-11-21
KR20010014658A (ko)	2001-02-26
CA2302965A1 (en)	2000-09-30
CN1699350A (zh)	2005-11-23
EA200000274A2 (ru)	2000-10-30
CO5160273A1 (es)	2002-05-30
IS5411A (is)	2000-10-02
SG115536A1 (en)	2005-10-28
SK287339B6 (sk)	2010-07-07
KR20020084903A (ko)	2002-11-13
HK1029790A1 (en)	2001-04-12
HUP0001353A3 (en)	2002-01-28
CA2302965C (en)	2004-02-17
AR018705A1 (es)	2001-11-28
GT200000037A (es)	2001-09-21
NZ503683A (en)	2001-09-28
SK4442000A3 (en)	2000-10-09
CN1215061C (zh)	2005-08-17
JP4074509B2 (ja)	2008-04-09
EA005892B1 (ru)	2005-06-30
HRP20000182A2 (en)	2001-04-30
EA004654B1 (ru)	2004-06-24
JP3420549B2 (ja)	2003-06-23
DE60032275D1 (de)	2007-01-25
SV2002000047A (es)	2002-01-23
BRPI0001486B8 (pt)	2021-05-25
PT1044969E (pt)	2007-05-31
DE60032275T2 (de)	2007-07-12
PA8491901A1 (es)	2001-12-14
TW553939B (en)	2003-09-21
ES2278578T3 (es)	2007-08-16
UY26086A1 (es)	2000-10-31
YU13200A (sh)	2002-10-18
EG22506A (en)	2003-03-31
EP1044969A2 (en)	2000-10-18
CN1276370A (zh)	2000-12-13
IS2468B (is)	2008-12-15
PL339330A1 (en)	2000-10-09
HU0001353D0 (en)	2000-06-28
UA70928C2 (ru)	2004-11-15
CZ299426B6 (cs)	2008-07-23
ATE348098T1 (de)	2007-01-15
NZ512818A (en)	2003-01-31
AP1265A (en)	2004-03-26
ID25427A (id)	2000-10-05
JP2000290262A (ja)	2000-10-17
AU781402B2 (en)	2005-05-19
OA11335A (en)	2003-12-10
PE20001599A1 (es)	2001-01-18
RS49836B (sr)	2008-08-07
DK1044969T3 (da)	2007-04-23
NO324745B1 (no)	2007-12-03
TNSN00064A1 (fr)	2005-11-10
EP1044969B1 (en)	2006-12-13
NO20001648L (no)	2000-10-02
MA25087A1 (fr)	2000-10-01
AP1655A (en)	2006-09-01
NO20001648D0 (no)	2000-03-30

Publication	Publication Date	Title
EA200000274A3 (ru)	2003-02-27	Способы получения и промежуточные соединения для получения противораковых соединений
ID25792A (id)	2000-11-02	Antibodi-antibodi terhadap cd40 manusia
PT1150966E (pt)	2003-01-31	Metodo de preparacao de 5-cianoftalido
EE200000642A (et)	2002-04-15	Suurendatud saagisega FAPalfa-spetsiifilised antikehad
PT1210113E (pt)	2006-07-31	Composicoes de vacinas de combinacao
PT1162973E (pt)	2005-08-31	Preparacao de cilostazole
ID27092A (id)	2001-03-01	Pembuatan ftalat anhidrida
AR028280A1 (es)	2003-04-30	Derivados de 2-amino-3-(alquil)-pirimidona
EE200200183A (et)	2003-06-16	Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
NO995134D0 (no)	1999-10-21	Forbedrede fremgangsmåter for fremstilling av aktivert protein C
PT1237827E (pt)	2003-10-31	Preparacao de acelerador de betao
NO20006021D0 (no)	2000-11-28	Fremgangsmåte for fremstilling av jern-dekstran forbindelse
EE200100383A (et)	2002-12-16	L-fenüülefriinvesinikkloriidi valmistamise meetod
EE04154B1 (et)	2003-10-15	Omeprasooli valmistamise meetod
EA199900319A1 (ru)	2000-06-26	Формованное топливо (варианты) и способы его получения
FR2816843B1 (fr)	2006-10-27	Inhibiteurs de l'enzyme 5 alpha-reductase
PT1246817E (pt)	2004-11-30	Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
EA200100505A1 (ru)	2001-10-22	Комплексный модификатор бетона и способ его приготовления
ID28577A (id)	2001-06-07	Metoda pemilihan waktu kalibrasi
ID28032A (id)	2001-05-03	TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
PT1228056E (pt)	2005-02-28	Metodo de preparacao de citaloprame
EP1272205A4 (en)	2004-05-06	SIALOADHESIN FACTOR-2 ANTIBODIES
PT1178984E (pt)	2003-06-30	Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20020183D0 (no)	2002-01-14	Fremgangsmåte for deacylering av lipodepsipeptider
NO20012099L (no)	2001-07-02	Fremgangsmåte for fremstilling av 4-arylpiperidin-3- karbinoler og beslektede forbindelser

Legal Events

Date	Code	Title	Description
2005-04-28	PC4A	Registration of transfer of a eurasian patent by assignment
2011-12-30	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM
2020-04-30	MK4A	Patent expired	Designated state(s): RU